

Serial No. 09/908,950 filed 7/19/01
Response of 10/30/07 to Office Action of 4/30/07

Amendments to the Drawings

The attached sheets of drawings include changes to Figures 1-2. Those sheets have been amended to annotate them with Sequence ID Numbers.

RECEIVED
CENTRAL FAX CENTER

OCT 30 2007

Serial No. 09/908,950 filed 7/19/01
Response of 10/30/07 to Office Action of 4/30/07

Remarks

Receipt is acknowledged of the Office Action of April 30, 2007 in the above-captioned matter. Reconsideration of all of the rejections and a three month extension of the time provided for response are respectfully requested. The Commissioner is hereby authorized to debit all amounts deemed required, including the fee for the extension, from Deposit Account No. 50-1604.

Sequence Rules and Objection to the Specification

Further to the objection to the specification, replacement drawings are enclosed. In the replacement drawings, the specified poly A and poly T sequences are enumerated with Sequence ID Numbers. (The nucleotide sequences of the capture sequences are not listed therein as they can be Cy3 or Cy5 or another custom sequence, as explained in the specification).

A paper sequence listing is enclosed as well. To facilitate submission of a corresponding computer sequence listing, counsel inquires herein whether such a listing may be emailed to the Examiner or to the Patent Office (and if so, which email address should be utilized). It is also noted that the present submission includes no new matter, as the sequences herein were presented in the specification when the application was originally filed.

Accordingly, reconsideration and withdrawal of the objections is respectfully requested.

Rejections Under 35 U.S.C. §§101 and 112

In the Office Action, various claims were rejected under §§101 and 112. Further thereto, the

Serial No. 09/908,950 filed 7/19/01
Response of 10/30/07 to Office Action of 4/30/07

claims have been amended as set forth above. Accordingly, reconsideration and withdrawal of the §§101 and 112 rejections is respectfully requested.

Rejections Under 35 U.S.C. §103


In the Office Action, the Examiner indicated that Applicants' arguments were not deemed persuasive because it was deemed that the scope of the claims do not exclude cDNA. Accordingly, to facilitate an allowance all of the claims have been amended as set forth above to expressly recite detection of RNA in the target sample. It is respectfully noted that the scope of the prior claims only referred to RNA reagent, and were not intended to include detection of cDNA. It is likewise noted that the specific purpose of the claimed inventions is to provide a method for direct detection of RNA (which overcomes the stability issues associated with RNA in the art without needing use of cDNA). Accordingly, reconsideration and withdrawal of the rejections is respectfully requested.

In addition, claims 57 and 58 were indicated as not having been examined. In view of the amendments above, examination of the claims is respectfully requested.

As a result, favorable action on the application is respectfully requested.

Dated: October 30, 2007

Respectfully submitted,



Morris E. Cohen (Reg. No. 39,947)
1122 Coney Island Avenue, Suite 216
Brooklyn, New York 11230-2345
(718) 859-8009 (phone)
(718) 859-3044 (fax)